Novel nanoscale vanillin based covalent triazine framework as a novel carrier for sustained release of imatinib

Abstract

AbstractThis study deal with introducing a novel biocompatible porous nanomaterial for anticancer drug delivery. For this purpose, a porous covalent triazine framework (CTF) was prepared by a solvothermal reaction. The structure and morphology characterization of the synthesized CTF was done through different techniques. Imatinib (IMA) were loaded thoroughly into the CTF to form IMA‐loaded CTF (IMA@CTF) in which drug loading and encapsulation efficiency was calculated to be 82% and 96%, respectively. The releases of 73% and 48%% after 72 h for the IMA@CTF were obtained in pH = 5.3 and pH = 7.4, respectively, which reflected pH‐dependent behavior as well as sustained imatinib release. Biocompatibility and cytotoxicity effect of CTF and IMA@CTF assessed after 48 h incubation with normal cell line L929 as well as K562 cells. The biocompatibility study indicated reasonable biosafety of the synthesized CTF and MTT assay on chronic myeloma cancer cells showed no reduction effect in the anticancer activity of IMA after incorporating into CTF. The results demonstrated the synthesized CTF could be as a promise anti‐cancer drug carrier.